Novalar Pharmaceuticals - Top 20 VC deals of 2007

Company: Novalar Pharmaceuticals
Based: San Diego, CA
Amount: $42
Round: Fourth
Investors: Domain Associates, Montreux Equity Partners, New Enterprise Associates, S.R. One, Undisclosed Venture Firm

Scoop: Novalar is focused on developing oral healthcare therapies. It's lead product--NV-101--is designed to reverse the lingering and debilitating lip and tongue numbness associated with local dental anesthesia. It was submitted to the FDA in June of 2007. The funding will help Novalar commercialize NV-101 if approved by the FDA.

Novalar Pharmaceuticals - Top 20 VC deals of 2007

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i